Pei Wang
Senior Vice President, Clinical Development & CMC Eureka Therapeutics
Dr. Wang is Senior Vice President of Clinical Development and CMC at Eureka Therapeutics and has over 17 years of experience advancing T-cell therapies from early research through clinical development. At Eureka, she directs clinical development and manufacturing strategy across multiple programs and serves as Principal Investigator for the California Institute for Regenerative Medicine (CIRM)-funded ARYA-2 pediatric cancer initiative. Her work has advanced programs earning FDA Fast Track, Rare Disease, Orphan Drug and Regenerative Medicine Advanced Therapy designations and driven successful IND submissions and strategic collaborations with academic institutions and industrial partners. Dr. Wang earned a Ph.D. from The University of Texas at Austin and a B.S. from Peking University.
Seminars
- Detailing the transition process between FDA, EMA and IIT clinical programs to streamline clinical development across borders
- Discussing strategies for incorporating early clinical readouts from international studies to enable faster decision making before US trial initiation
- Evaluating evolving US regulatory comfort with globally generated data to showcase how aligned global development strategies can accelerate innovation while maintaining regulatory rigor
